Literature DB >> 6437702

Evaluation of the degree of desialylation of serum C1-inactivator and haemopexin.

N S Serbource-Goguel Seta, M C Bordas, J M Féger, J A Davy, G M Durand.   

Abstract

The calibration curves for evaluating the degree of desialylation of C1-inactivator (sialic acid content 12.5%) and haemopexin (sialic acid content 4%) have been plotted. No desialylation of either glycoprotein occurs in normal subjects. In the patients (liver damage) studied, C1-inactivator is often desialylated, whereas haemopexin is not. In a previous report, we had shown that alpha1-acid glycoprotein is more often desialylated than alpha1-antitrypsin. Thus, it appears that the degree of desialylation of the sialic acid-rich glycoproteins is a more sensitive index of the severity of hepatic injury than that of the sialic acid-poor glycoproteins. This could be due to a defect in the sialylation process during synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437702     DOI: 10.1016/0009-8981(84)90073-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Characterization of C1 inhibitor binding to neutrophils.

Authors:  N S Chang; R J Boackle; R W Leu
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.

Authors:  T Hada; T Ohue; H Imanishi; H Nakaoka; A Hirosaki; S Shimomura; M Fujikura; Y Matsuda; T Yamamoto; Y Amuro
Journal:  Gastroenterol Jpn       Date:  1990-12

3.  Increased plasma alpha (1 --> 3)-L-fucosyltransferase activities in patients with hepatocellular carcinoma.

Authors:  T Hada; K Fukui; M Ohno; S Akamatsu; S Yazawa; K Enomoto; K Yamaguchi; Y Matsuda; Y Amuro; N Yamanaka
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.